FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy.

@article{Katz2011FLTPETMN,
  title={FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy.},
  author={Sharyn I Katz and Lanlan Zhou and Thomas A Ferrara and Wenge Wang and Patrick A. Mayes and Charles D. Smith and Wafik S El-Deiry},
  journal={International journal of oncology},
  year={2011},
  volume={39 1},
  pages={91-100}
}
FDG (18F-deoxy-glucose) is the current gold standard for PET imaging. FLT (3'-deoxy-3'-(18F-fluorothymidine), a PET imaging marker of proliferation, has been proposed as an alternative to FDG for the assessment of therapeutic response. We examined the therapeutic predictive value of FLT-PET and FDG-PET using CALU-6, a human, p53-null, non-small cell lung cancer cell line with comparison of combined targeted therapy, TRAIL and sorafenib, versus combined conventional chemotherapy, docetaxel and… CONTINUE READING